| (Values in U.S. Thousands) | Jun, 2021 | Mar, 2021 | Dec, 2020 | Sep, 2020 | Jun, 2020 |
| Sales | 0 | 0 | 10 | 0 | 0 |
| Sales Growth | unch | -100.00% | unch | unch | unch |
| Net Income | -2,470 | -2,580 | -2,420 | -2,010 | -1,720 |
| Net Income Growth | +4.26% | -6.61% | -20.40% | -16.86% | +11.79% |
Eyegate Pharm WT (EYEGW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
EyeGate Pharmaceuticals, Inc. is a pharmaceutical company which is engaged in developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The company's technology consists of EyeGate(R) II Delivery System. Its product pipeline includes EGP-437 which is in different clinical stage. EyeGate Pharmaceuticals, Inc. is based in WALTHAM, MA.